FENC
Fennec Pharmaceuticals Inc.
FENC has slightly lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has a slight edge over FENC overall, supported by stronger fundamentals.
FENC Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Healthy | |
| Unavailable |
FENC's revenue, profitability and cash flow are currently healthy. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
FENC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $10.90 | — |
| Current | 1,090x | $10.90 | — |
| Cheap | N/A | N/A | N/A |
| Fair | N/A | N/A | N/A |
| Expensive | N/A | N/A | N/A |
Historical ranges are pointers, not guarantees.
FENC has the edge over OSCR in the historical PE scenario, which offers more potential upside but is not a forecast.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
FENC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for FENC, with profitability improving. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
FENC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.68 | +6660% |
| Q3 2026 | $0.01 | +$0.25 |
| Q2 2026 | -$0.13 | +$0.30 |
| Q1 2026 | -$0.29 | +$0.23 |
| Q4 2025 | -$0.34 | -$0.27 |
| Q3 2025 | -$0.24 | +$0.83 |
| Q2 2025 | -$0.43 | +$0.50 |
| Q1 2025 | -$0.52 | +$0.42 |
| Q4 2024 | -$0.07 | +$1.51 |
FENC has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
FENC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.6M | +57% |
| Q2 2026 | $17.9M | +85% |
| Q1 2026 | $15.1M | +73% |
| Q4 2025 | $13.8M | +74% |
| Q3 2025 | $12.5M | +79% |
| Q2 2025 | $9.7M | +33% |
| Q1 2025 | $8.8M | -66% |
| Q4 2024 | $7.9M | -20% |
FENC's revenue is recovering but still below its 2024 peak: $20M last quarter, up 57% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | +25 points |
| Q2 2026 | 9.7% | +38 points |
| Q1 2026 | -0.8% | +8.4 points |
| Q4 2025 | -19% | -6.8 points |
| Q3 2025 | -1.5% | +73 points |
| Q2 2025 | -28% | +41 points |
| Q1 2025 | -9.2% | -63 points |
| Q4 2024 | -12% | +6.5 points |
FENC has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
FENC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.7M | +348% |
| Q2 2026 | $50K | +$3.7M |
| Q1 2026 | $2.4M | +$6.7M |
| Q4 2025 | -$6M | -$4.5M |
| Q3 2025 | $1.5M | +$3.7M |
| Q2 2025 | -$3.7M | +$4.7M |
| Q1 2025 | -$4.3M | -111% |
| Q4 2024 | -$1.5M | +$3.4M |
FENC's free cash flow has turned positive after six years mostly in the red: $3M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
FENC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.5% | +1.6M shares |
| 1 year | +37% | +10.2M shares |
| 3 years | +43% | +11.5M shares |
| 5 years | +46% | +12.1M shares |
| Available history | +91% | +18.2M shares |
FENC has 38M diluted shares, up 37% from a year ago.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over FENC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
FENC Net Leverage
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
FENC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.6 | Neutral |
| Stochastic | 26.3 | Neutral |
FENC's weekly RSI is 56 (neutral) and its Stochastic is 26 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
FENC PE vs Healthcare Sector
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
FENC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.3 | 5.6% above |
| 20 week MA | $10.7 | 1.6% above |
| 50 week MA | $9.05 | 20% above |
| 100 week MA | $8.25 | 32% above |
| 200 week MA | $8.06 | 35% above |
FENC is in an uptrend: it's above all five of its weekly moving averages, and 35% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
FENC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.23 | $7.16 | +15% |
| 2021 | $7.16 | $4.49 | -37% |
| 2022 | $4.49 | $9.78 | +118% |
| 2023 | $9.78 | $11.2 | +15% |
| 2024 | $11.2 | $6.22 | -45% |
| 2025 | $6.22 | $8.09 | +30% |
| 2026 YTD | $8.09 | $10.9 | +35% |
FENC's yearly returns have swung widely, from +118% in 2022 to −45% in 2024. It's up 35% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over FENC on returns for 2026, with the stronger performance.